Table 3.
Ochratoxin | Treatment | Experimental Period | Impacts/Chicken Type | Publication Date | References |
---|---|---|---|---|---|
Feed Efficiency and Growth Performance | 0.4 or 0.8 mg/kg | 35-d | Decrease in FI and BW/Broiler | 2006 | [128] |
5 mg/kg | 365-d | Decrease in EPR and EW/Layer | 2010 | [129] | |
0.05 mg/kg | 28-d | Decrease in BWG/Broiler | 2015 | [130] | |
0.1 mg/kg | 42-d | Decrease in BW/Broiler | 2016 | [131] | |
0.5 and 1 mg/kg | 35-d | Reduced in FI and GR/Broiler | 2021 | [16] | |
Antioxidants status | 1 mg/kg | 24-h | Increase in MDA, mRNA expression of apoptosis-associated genes, and apoptosis rate; decrease in SOD, and GSH levels/Broiler | 2018 | [132] |
106,654 and 1126 µg/kg | 21-d | Increase in liver and kidney MDA, GSH in blood plasma and liver/Broiler | 2019 | [133] | |
50 µg/kg | 21-d | Increase in kidney MDA and decrease in GSH, SOD, CAT (m-RNA expression), SOD (m-RNA expression) and GSH-Px (m-RNA expression)./Broiler | 2020 | [134] | |
Blood Parameters | 1 mg/kg | 1-d | Increase in AST and ALT/Broiler | 2018 | [132] |
3 mg/kg | 10-d | Increase in blood Glu, U.A, ALT and AST/Broiler | 2021 | [135] | |
Internal organs | 2.5 mg/kg | 21-d | An increase in kidney weight/Broiler | 1999 | [136] |
0.4 or 0.8 mg/kg | 35-d | An increase in gizzard mass/Broiler | 2006 | [128] | |
0.05 mg/kg | 28-d | Changes in the anatomy of the intestinal mucosa/Broiler | 2015 | [130] | |
0.1 mg/kg | 42-d | OTA residues in the liver and increase weight/Broiler | 2016 | [131] | |
3 mg/kg | 10-d | Hemorrhages on the epicardium and duodenal mucosa, catarrhal enteritis/Broiler | 2021 | [135] |
BW = body weight; BWG = body weight gain; FI = feed intake; EPR = egg production rate; EW = egg weight; GR = growth rate; MDA = malondialdehyde; GSH = glutathione; SOD = superoxide dismutase; GSH-Px = glutathione peroxidase; AST = aspartate aminotransferase; ALT = alanine aminotransferase; Glu = glucose; U.A = uric acid; OTA = Ochratoxin A.